Skip over global navigation links
U.S. Department of Health and Human Services

BARDA partners with GlaxoSmithKline to develop new class of antibiotic against bioterrorism threats and Gram-negative infections

Date: September 6, 2011

Company: GlaxoSmithKline of Philadelphia

Contract amount: The contact is for $38.5 million in the first two years and can be extended for a total of four years, up to a total of $94 million. Under the contract, BARDA will provide technical and financial support for the development of GSK2251052, sharing the cost and drug development risk.

About the contract:  This contract supports advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization – the first such drug in 30 years. The contract support studies to evaluate the efficacy of GSK2251052 against bioterrorism threats, Phase II clinical trials using the drug to treat ventilator-associated pneumonia, and Phase III clinical trials using the drug to treat complicated intra-abdominal infections. In addition, the contract will support initial laboratory testing to determine if the drug also provides protection against multi-drug resistant pathogens, including those containing the New Delhi Metallo-beta-lactamase-1 (NDM-1) resistance gene.

Additional information: The contract is the third to be funded under the resulting new Broad Spectrum Antimicrobials Program led by BARDA. BARDA is seeking additional proposals for broad-spectrum antimicrobials that could potentially treat or prevent illness due to biological threat agents.  Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at

Press Release:  BARDA partners to develop new class of antibiotic

Procurement Announcement:  Contract Award under BARDA-CBRN-BAA-10-100-SOL-00012

PHE Newsroom

Submit an Inquiry


Watch, Listen, Subscribe

Facebook Exit Icon Twitter Exit Icon YouTube Exit Icon
Email via GovDelivery Exit Icon LinkedIn Exit Icon

  • This page last reviewed: January 12, 2018